RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

RY

161.73

+2.56%↑

TD

93.32

+1.91%↑

BMO

135.42

+2.9%↑

CM

94.74

+3.18%↑

BNS

69.28

+2.87%↑

Search

Brown & Brown Inc

Cerrado

SectorFinanzas

65.24 -0.08

Resumen

Variación precio

24h

Actual

Mínimo

64.31

Máximo

65.91

Métricas clave

By Trading Economics

Ingresos

25M

255M

Ventas

63M

1.7B

P/B

Media del Sector

20.652

54.484

Rentabilidad por dividendo

0.97

Margen de beneficios

15.279

Empleados

22,888

EBITDA

27M

556M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+25.77% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.97%

4.92%

Próximas Ganancias

27 abr 2026

Fecha Próximo Dividendo

20 may 2026

Próxima Fecha de Ex Dividendo

11 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-5B

22B

Apertura anterior

65.32

Cierre anterior

65.24

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

171 / 441 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Brown & Brown Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 mar 2026, 23:31 UTC

Acciones populares

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Ganancias

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 abr 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Adquisiciones, fusiones, absorciones

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Ganancias

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Charlas de Mercado
Ganancias

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Charlas de Mercado

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Adquisiciones, fusiones, absorciones

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Charlas de Mercado

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Ganancias

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Ganancias

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Ganancias

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Ganancias

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Ganancias

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Ganancias

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Ganancias

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Ganancias

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Charlas de Mercado
Ganancias

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Ganancias

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Ganancias

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Ganancias

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Ganancias

Nike CEO: Converse Remains Important to Portfolio

Comparación entre iguales

Cambio de precio

Brown & Brown Inc previsión

Precio Objetivo

By TipRanks

25.77% repunte

Estimación a 12 Meses

Media 82.08 USD  25.77%

Máximo 100 USD

Mínimo 73 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Brown & Brown Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

15 ratings

3

Comprar

12

Mantener

0

Vender

Puntuación técnica

By Trading Central

110.6 / 117.76Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

171 / 441 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Brown & Brown Inc

Brown & Brown, Inc. markets and sells insurance products and services in the United States, Canada, Ireland, the United Kingdom, and internationally. It operates through four segments: Retail, National Programs, Wholesale Brokerage, and Services. The Retail segment provides property and casualty, employee benefits insurance products, personal insurance products, specialties insurance products, risk management strategies, loss control survey and analysis, consultancy, and claims processing services. It serves commercial, public and quasi-public entities, professional, and individual customers. The National Programs segment offers professional liability and related package insurance products for dentistry, legal, eyecare, insurance, financial, physicians, real estate title professionals, as well as supplementary insurance products related to weddings, events, medical facilities, and cyber liabilities. This segment also provides public entity-related and specialty programs through a network of independent agents; and program management services for insurance carrier partners. The Wholesale Brokerage segment markets and sells excess and surplus commercial and personal lines insurance through independent agents and brokers. The Services segment offers third-party claims administration and medical utilization management services in the workers' compensation and all-lines liability arenas, Medicare Set-aside, Social Security disability, Medicare benefits advocacy, and claims adjusting services. Brown & Brown, Inc. was founded in 1939 and is headquartered in Daytona Beach, Florida.
help-icon Live chat